The launch of generic Semaglutide in India has made an immediate and dramatic impact on the obesity and diabetes drug market, with CLSA’s latest healthcare channel check note revealing a rapid market share gain that has caught even optimistic analysts off-guard. According to CLSA, within just 10 days of the generic Semaglutide launch in March 2026, its market share jumped from 25% to 33% — a sharp 8 percentage point gain in less than a fortnight.
The beneficiaries have been clearly identified. CLSA’s note points to Torrent Pharmaceuticals, Dr. Reddy’s Laboratories and Zydus Lifesciences as the primary gainers from the increased market share, citing their well-established sales forces and strategic focus on diabetic and cardiovascular therapies as the key competitive advantages that have allowed them to capture the incremental share quickly. All three companies have strong existing relationships with endocrinologists and cardiologists — the two specialist communities driving the bulk of Semaglutide prescriptions — giving them a significant distribution and detailing edge over competitors entering this space.
The flip side of generic Semaglutide’s rise has been a dent in the market dominance of Eli Lilly’s Tirzepatide, sold under the brand name Mounjaro. CLSA’s channel checks show Mounjaro’s market share declining from 61% in February 2026 to 56% in March 2026, a five percentage point erosion in a single month. While Tirzepatide continues to lead the market by a wide margin, the trajectory is clear — generic Semaglutide is eating into its share at a pace that could accelerate materially as prescription-led demand builds.
CLSA flagged an important nuance for investors to keep in mind, however. The brokerage noted that much of the initial increase in Semaglutide sales has been driven by an inventory push to stockists rather than end-patient prescription-driven demand. This means the full organic demand picture is not yet visible in the data. CLSA believes prescription-led sales should pick up meaningfully in the coming months, which would represent a second, more durable wave of volume growth for Torrent, Dr. Reddy’s and Zydus — making the current channel fill a floor rather than a ceiling for future performance.
The Semaglutide opportunity in India is part of a broader global narrative around GLP-1 receptor agonists, a class of drugs that has reshaped the treatment landscape for type 2 diabetes and obesity. With generics now entering the Indian market at accessible price points, the addressable patient population expands considerably — and the companies best positioned to capture this expansion are those with the strongest metabolic disease franchises, physician relationships and manufacturing scale.